Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review

Spinal Cord Stimulation for Spasticity: Historical Approaches, Current Status, and Future Directions

“…Conversely, drug titration is usually more complicated and associated with increased risk relative to an adjustment in the SCS power setting. Detailed contemporary assessments of its implementation in the treatment of spasticity have been presented recently in an important series of best‐practices papers in ITB .…”

“…Conversely, drug titration is usually more complicated and associated with increased risk relative to an adjustment in the SCS power setting. Detailed contemporary assessments of its implementation in the treatment of spasticity have been presented recently in an important series of best-practices papers in ITB (41)(42)(43)(44)(45). The earliest mention of SCS for spasticity dates to 1973 when Cook and Weinstein reported unexpected improvements in spasticity in a patient with MS who was trialing SCS for pain (46).…”

Long‐Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury

“…To our knowledge, this is the first study to describe ITB dose stability in adults with spasticity after acquired brain injury. Previous studies assessing ITB dosing in brain‐injured populations have been limited by either small sample sizes, ranging from 8 to 25 subjects [5,9‐11,14], and/or follow‐up periods of less than 3 years [5,8,9,11,13]. Alternatively, we report on a cohort of 42 adult patients with spasticity of cerebral origin secondary to TBI, stroke, or HIE with mean duration of ITB therapy of 8.5 years.…”

“…Previous studies have reported a wide range of average daily ITB doses for managing spasticity of cerebral origin, including rates from 265 to 628.5 μg/d [4,5,8‐11,13]. These studies are limited by small sample sizes [5,9,10,14], heterogeneous populations [10,11], and short follow‐up time frames [5,8,9,11,13]. In addition, no previous studies have investigated changes in ITB dose over time in the TBI, stroke, and HIE population; thus, relative dose stability is unknown.…”

Intrathecal Baclofen Infusion Pumps in the Treatment of Spasticity: A Retrospective Cohort Study in a Portuguese Centre

“…These quantitative scales are not only used to assess the degree of spasticity, but also to evaluate treatment efficacy. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] Baclofen acts on γ-Aminobutyric acid (GABA)-B receptors inhibiting the release of excitatory neurotransmitters and reducing spasticity. As a result of its low lipid solubility, oral baclofen barely crosses the blood brain barrier.…”